Princeton Portfolio Strategies Group LLC raised its holdings in shares of Medtronic PLC (NYSE:MDT) by 3.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 85,790 shares of the medical technology company’s stock after buying an additional 2,980 shares during the quarter. Medtronic comprises about 2.1% of Princeton Portfolio Strategies Group LLC’s holdings, making the stock its 14th largest position. Princeton Portfolio Strategies Group LLC’s holdings in Medtronic were worth $7,814,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Global Financial Private Capital LLC purchased a new position in shares of Medtronic during the 1st quarter worth approximately $503,000. Xact Kapitalforvaltning AB grew its stake in shares of Medtronic by 3.0% in the 1st quarter. Xact Kapitalforvaltning AB now owns 249,287 shares of the medical technology company’s stock worth $22,705,000 after buying an additional 7,333 shares during the last quarter. AJO LP grew its stake in shares of Medtronic by 12.4% in the 1st quarter. AJO LP now owns 63,749 shares of the medical technology company’s stock worth $5,806,000 after buying an additional 7,017 shares during the last quarter. Stanley Laman Group Ltd. grew its stake in shares of Medtronic by 4.1% in the 1st quarter. Stanley Laman Group Ltd. now owns 12,187 shares of the medical technology company’s stock worth $1,110,000 after buying an additional 485 shares during the last quarter. Finally, Reynders McVeigh Capital Management LLC lifted its position in Medtronic by 2.6% in the 1st quarter. Reynders McVeigh Capital Management LLC now owns 6,292 shares of the medical technology company’s stock valued at $573,000 after acquiring an additional 161 shares in the last quarter. Institutional investors and hedge funds own 80.10% of the company’s stock.
Several equities analysts recently issued reports on MDT shares. Barclays reaffirmed a “buy” rating and issued a $104.00 price objective on shares of Medtronic in a research report on Wednesday, February 20th. Oppenheimer set a $104.00 price objective on Medtronic and gave the company a “buy” rating in a research report on Wednesday, February 20th. UBS Group upped their price objective on Medtronic to $112.00 and gave the company a “buy” rating in a research report on Friday. Needham & Company LLC reaffirmed a “buy” rating and issued a $121.00 price objective on shares of Medtronic in a research report on Monday, May 27th. Finally, Zacks Investment Research raised Medtronic from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Eight research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Medtronic has a consensus rating of “Buy” and a consensus price target of $103.95.
Shares of MDT stock opened at $97.50 on Friday. Medtronic PLC has a 52-week low of $81.66 and a 52-week high of $100.15. The company has a quick ratio of 2.15, a current ratio of 2.59 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $130.80 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 2.51 and a beta of 0.68.
Medtronic (NYSE:MDT) last issued its quarterly earnings data on Thursday, May 23rd. The medical technology company reported $1.54 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.07. The firm had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.12 billion. Medtronic had a return on equity of 14.16% and a net margin of 15.15%. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business posted $1.42 earnings per share. Analysts expect that Medtronic PLC will post 5.46 EPS for the current year.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.